Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

VWS Wong, S Chitturi, GLH Wong, J Yu… - The Lancet …, 2016 - thelancet.com
Non-alcoholic fatty liver disease affects 20–40% of the population. Its active form, non-
alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation …
被引用次数：191 相关文章

[引用][C] Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

VWS Wong, S Chitturi, GLH Wong, J Yu… - The Lancet …, 2016 - cir.nii.ac.jp

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

VWS Wong, S Chitturi, GLH Wong… - The lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease affects 20-40% of the population. Its active form, non-
alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation …

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

VWS Wong, S Chitturi, GLH Wong, J Yu… - The Lancet …, 2016 - Elsevier
Non-alcoholic fatty liver disease affects 20–40% of the population. Its active form, non-
alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation …

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.

VW Wong, S Chitturi, GL Wong, J Yu… - The lancet …, 2016 - europepmc.org
Non-alcoholic fatty liver disease affects 20-40% of the population. Its active form, non-
alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation …